Bial-Portela & CA SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bial-Portela & CA SA
Coronavirus Update: India Approves Remdesivir, Ex-Biogen Employee Charged
A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.
Neurocrine Will Delay Ongentys Launch, But It Thinks Differentiation Is Clear
Ongentys, now approved as adjunctive therapy in Parkinson’s disease, will offer a convenience advantage over generic COMT inhibitors. The company will delay launch due to pandemic and manufacturing issues.
Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Neurocrine Adds Epilepsy Assets From Xenon
Neurocrine plans to advance XEN901 into Phase II in a rare pediatric epilepsy indication while eyeing opportunity in adult focal epilepsy. Xenon increases its runway to develop a pair of mid-stage epilepsy drugs.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.